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Abstract
Childhood obesity is an identified risk factor for several long-term health issues such as type 2
diabetes mellitus (T2DM). According to the Centers for Disease Control and Prevention (CDC),
diabetes is the seventh leading cause of death within the United States. The CDC has
implemented an evidence-based program, The National Diabetes Prevention Program (DPP), to
prevent the development of T2DM among individuals with prediabetes. Prediabetes is defined as
having elevated glucose levels glycated hemoglobin [A1C] levels between 5.7%-6.5%) that are
not elevated enough to meet diabetes diagnosis criteria (A1C levels > 6.5%). The DPP is a
lifestyle change program that has shown that the risk for developing T2DM can be reduced by
50% by increased physical activity and healthier eating practices. There has been a significant
increase in T2DM within the pediatric population over past twenty years, which is greatly
affected by obesity. Evidenced-based lifestyle interventions for children are important. Several
programs are emerging that utilize the basis of the DPP lifestyle interventions that have been
proven successful in adults in the youth population. Of these programs, Riley Children’s Health
Get a Move On and Powerhouse, University of Nevada at Las Vegas adapted DPP program, and
Yale University’s Bright Bodies Management Program have shown success in the youth
population. The youth diabetes prevention program (YDPP) requires further exploration and
identification of best practices to implement in school based and/or youth settings to combat the
epidemic of type 2 diabetes in the youth population.
Keywords: Diabetes Prevention Program, childhood, obesity, diabetes, lifestyle change,
Youth Diabetes Prevention Programs
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The American Pediatric Type 2 Diabetes Epidemic: Considerations for Targeted Diabetes
Prevention Programs
Diabetes mellitus (DM), commonly referred to as diabetes, is a complex metabolic
disorder that occurs when the pancreas does not produce enough insulin or the body does not
effectively use the insulin produced to regulate glucose levels (World Health Organization
[WHO], 2016). There are two common forms of diabetes, type 1 diabetes (T1DM), formerly
known as insulin-dependent or juvenile-onset diabetes, and type 2 diabetes (T2DM), formerly
known as non-insulin dependent or adult-onset diabetes (WHO, 2016). Other less common forms
of diabetes include gestational diabetes, neonatal diabetes, and maturity-onset diabetes of the
young (American Diabetes Association [ADA], 2017). In T1DM, the body’s immune system
destroys insulin-producing beta cells, resulting in reduction or elimination of insulin production,
which in turn reduces the ability to transport glucose across cell membranes, thus denying the
cells glucose to store as glycogen, or metabolize for energy needed for daily cellular function
(WebMD, 2017). T1DM is an autoimmune disorder and is, therefore, not preventable through
behavioral modifications (Basile, Guy, Schwartz, & Grant, 2014). In contrast, T2DM, the most
common form of diabetes, is characterized by normal or higher than normal levels of insulin,
with concomitant insulin resistance due to the actions of the body’s fat cells or adipocytes
interfering with the action of insulin. T2DM can develop at any age and is on the rise in adults
and (Romero, 2016) in children and adolescents (WebMD, 2017). T2DM is preventable through
lifestyle changes including improved dietary habits and increased physical activity (Tuso, 2014).
Diabetes is a major public health concern in the United States and was the seventh
leading cause of death within the United States (ADA, 2016a). Thirty years ago, T2DM was a
rare diagnosis in children and adolescents. However, in the mid-1990s, investigators identified
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an increasing incidence of T2DM worldwide (Reinehr, 2013) and an increase in prevalence and
degree of obesity in children (6 to 11 years) and adolescents (12 to 19 years) in the United States
(Reinehr, 2013). The literature indicates that in the past 40 years, obesity levels in children and
adolescents in the United States have tripled (Bassett, John, Conger, Fitzhugh, & Poe, 2015).
Obesity in early childhood is associated with numerous chronic conditions with childhood onset,
including T2DM, hypertension, and cardiovascular disease, as well as an increased risk of
remaining overweight or obese in adulthood with persistence and progression of the same
chronic conditions (Zilanawala et al., 2015). The childhood obesity epidemic has led to an
exponential increase in T2DM in children and adolescents (Figure 1) (Brar, Mengwall, Franklin,
& Fierman, 2014).

Figure 1. T2DM in children and adolescents. Copied from Romero, 2016, p. 14.
This rapid increase in T2DM in children and adolescents in the United States represents a
major public health issue due to the increased risk for chronic complications including
cardiovascular disease, nerve damage, kidney disease, and vision loss (Romero, 2016).
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Approximately 208,000 (0.25%) Americans under the age of 20 have been diagnosed with
diabetes (Centers for Disease Control and Prevention [CDC], 2015b).
There are several ongoing efforts to combat and prevent T2DM with early detection,
including a recent focus on subclinical precursors to diabetes. Prior to developing diabetes,
individuals often exhibit prediabetes (CDC, 2015a), a condition in which people have higher
than normal blood glucose levels but not high enough for a diabetes diagnosis (Tuso, 2014). The
National Diabetes Prevention Program (NDPP) was a major multifaceted clinical study that
aimed to determine if lifestyle change (including nutrition changes and increased physical
activity or the use of oral diabetes drugs) could prevent or delay the onset of T2DM (National
Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], 2008). The NDPP reported
that lifestyle changes resulted in weight loss that can prevent and/or delay T2DM (ADA, 2016a).
The use of the oral diabetes drug metformin can delay the onset of T2DM as well (NIDDK,
2008).
While the NDPP has only focused its efforts at preventing the onset of diabetes in adults
to date, the American Diabetes Association (ADA) now recommends screening at-risk children
using fasting plasma glucose (FPG) or oral glucose tolerance test (OGTT) every two years
beginning at ten years of age (Brar et al., 2014). Children that are at-risk for T2DM are
identified as overweight and have a least two additional risk factors for T2DM including family
history, categorized as belonging to a racial or ethnic minority, low birth weight, or maternal
history of gestational diabetes during the child’s gestation (Hannon, 2014). The early detection
of hyperglycemia in children and/or adolescents is integral to the prevention of developing
T2DM.
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Statement of Purpose
The purpose of this review was to: 1) describe the pediatric epidemic of T2DM in the
United States and its implications and 2) to identify evidence-based childhood/adolescent
prediabetes interventions akin to the National Diabetes Prevention Program for adults. In the
potential absence of appropriate existing programs the project was designed to offer
recommendations for modifying the adult NDPP for the child and adolescent population.
The following sections first describe the biological basis and sequelae of diabetes and
prediabetes, their treatment, and the long-term public health implications driving the current
national movement for prevention. Then a review of emergent diabetes prevention programs
tailored to the childhood/adolescent demographic is presented along with recommendations to
improve programs to prevent the onset of T2DM in children.
Overview of Diabetes
The human body depends on food as an energy source to maintain necessary metabolic
functions. Diabetes is a category of metabolic disorder negatively affecting how the human body
utilizes food as an energy source (CDC, 2015a). In the human body, the pancreas creates and
secretes the hormone insulin to metabolize glucose as an energy source for bodily function
(CDC, 2015a). Individuals with diabetes have glucose levels higher than is physiologically safe,
a pathological condition known as hyperglycemia (CDC, 2014). Hyperglycemia can occur due
to a lack of insulin produced by the pancreas to metabolize glucose (characteristic of T1DM) or
because the insulin produced is ineffective in metabolizing the glucose (insulin resistance,
characteristic of T2DM) (CDC, 2014). Symptoms of hypergylcemia include any sugar excreted
in the urine, frequent urination, and/or increased thirst (ADA, 2014). If left untreated, persistent
hyperglycemia can lead to a serious and potentially fatal condition, diabetic ketoacidosis (DKA)
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(ADA, 2014). DKA occurs when an excessive amount of glucose builds in the bloodstream
without transport of glucose into the cells. The cells then begin to burn fat and ketogenic amino
acids for energy, which produces ketones (ADA, 2014). Ketones are chemical byproducts
produced by the breakdown of fat and ketogenic amino acids by the body for energy use (ADA,
2014). An excessive amount of ketones can cause the blood pH level to drop to acidic levels (pH
< 7) from the usual slightly basic pH (pH = 7.35 – 7.45) (American Association for Clinical
Chemistry, 2014). This acidification can cause negative cardiovascular and respiratory
complications including hypertension, stroke, and nephropathy (ADA, 2014).
T1DM
There are two main types of diabetes, T1DM and T2DM. T1DM, previously known as
juvenile diabetes, is an autoimmune disorder in which insulin-producing cells of the pancreas
known as beta cells are attacked, preventing the production of insulin (Juvenile Diabetes
Research Foundation [JDRF], n.d.). Due to lack of insulin production, individuals with T1DM
have higher than recommended glucose levels in the body. T1DM is often characterized by an
acute onset and presents with symptoms including unexplained weight loss, sweet odorous
breath, increased thirst, increased appetite, change in mental status, and/or labored breathing
(JDRF, n.d.). Individuals with T1DM manage their glucose levels with administration of insulin,
eating a balanced diet at regular intervals, regulating carbohydrate intake, and moderate physical
activity throughout the day (JDRF, n.d.).
T2DM
The most common form of diabetes is T2DM: it makes up roughly 90% of all diagnosed
diabetes cases in the United States (The Obesity Society, 2016). This particular form of diabetes
is characterized by elevated blood glucose levels due to the impaired function of insulin
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produced by the pancreas also known as insulin resistance (NIDDK, 2014). Insulin resistance is
a condition in which adipocytes excrete chemical mediators that interfere with the intended
action of insulin. The pancreatic islet cells compensate by producing more insulin to facilitate
transport of glucose into muscle, liver, and fat cells (NIDDK, 2014). Over time there is gradual
attrition of the overworked islet cells in the pancreas, and the organ becomes unable to produce
enough insulin to satisfy the increased cellular need, resulting in sustained elevation of blood
glucose levels (NIDDK, 2014).
Prediabetes
In 2002, the ADA defined prediabetes as impaired fasting glucose (IFG) and/or impaired
glucose tolerance (IGT) (ADA, 2013). IFG is defined as having a fasting blood glucose of 100
to 125 mg/dl (after minimum fast of 8 hours) and IGT is defined as glucose level from 140 mg/dl
to 199 mg/dl measured two hours after consuming a glucose-rich drink of specific dose (ADA,
2013). The glycosolated hemoglobin (A1C) test is the primary test used for diabetes
management and research. This test is based on the rate of glucose to hemoglobin, the protein in
red blood cells that carries oxygen (NIDDK, 2014). (The A1C diagnostic test and ranges are
described more fully in the following section.) Individuals that have high blood glucose or
hemoglobin A1C levels (between 5.7%-6.4%) are diagnosed with prediabetes (NIDDK, 2014).
In 2012 it was reported that 86 million adult (> 20 years) Americans had prediabetes, an
increase from the 2010 report of 79 million prediabetic adults (ADA, 2016b). A diagnosis of
prediabetes is an indication that an individual is at greater risk than non-prediabetic individuals
to develop T2DM (CDC, 2016c).
Due to the associated chronic health risks with prediabetes, surveillance of prediabetes
allows for better prediction of diabetes trends (Abraham & Fox, 2013). Similarly, the clinical
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diagnosis of prediabetes allows for the identification of individuals that are more susceptible to
develop T2DM. Both lifestyle changes and metformin can independently delay the progression
from IGT to diabetes (Abraham & Fox, 2013). Identification of individuals with prediabetes
offers them the opportunity to modify their risk prior to the development of significant sequelae
(Abraham & Fox, 2013).
Hyperglycemia Categorization in Adults and Youth
While hyperglycemia can present with a variety of symptoms (e.g. frequent urination,
increased thirst, fatigue, blurred vision), the standard method for diagnosing hyperglycemic
conditions is through clinical blood tests (NIDDK, 2014). The standards used for youth (6 to 11)
and adolescents (12 to 18) are the same as adults. The three most common hematological
laboratory tests used for diagnosis of hyperglycemia are: glycosolated hemoglobin (A1C),
fasting plasma glucose (FPG), and the oral glucose tolerance test (OGTT) (NIDDK, 2014). The
same tests are used to screen for and diagnose diabetes and identify individuals with prediabetes
(ADA, 2016c). Figure 2 summarizes the parameters for diagnosis of prediabetes and diabetes for
each of the diagnostic tests.
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Figure 2. Diagnostic test ranges for diabetes. Source: American Diabetes Association, 2016c,
“Diagnosing diabetes and learning about prediabetes”.
Hemaglobin A1C Test
The A1C test reflects an individuals’ average blood glucose over the past two to three
months (ADA, 2014). In the human body, red blood cells are constantly forming and dying, but
typically live for three months. Thus the A1C test reflects the average of a person’s glucose over
the past three months (NIDDK, 2014). A normal A1C level is defined as greater than > 5.7%; an
A1C level that indicates prediabetes falls within range of the normal and diabetic A1C (5.7% <
6.5%); and an A1C level that indicates diabetes is greater than the prediabetic range (≥ 6.5%)
(NIDDK, 2014). In contrast to the FPG, there is a greater cost associated with the A1C test
(ADA, 2016c), but there are several advantages to utilizing the A1C test for prediabetes/diabetes
diagnosis. These advantages include no requirement to fast, greater pre-analytical specimen
stability, and less day-to-day fluctuation due to stress and/or illness (ADA, 2016c).
Fasting Plasma Glucose (FPG) Test
A fasting plasma glucose (FPG) test directly measures the blood glucose quantified a
milligrams per deciliter of blood (Mayo Clinic, 2014). The test requires that an individual
refrain from consuming food or drink, with the exception of water (fast) for at least eight hours
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prior to the test (ADA, 2014). An FPG level of 100 mg/dl is considered normal. Prediabetes is
diagnosed with an FPG level 100 mg/dl to125 mg/dl (100 mg/dl < 125 mg/dl) and diabetes is
diagnosed as an FPG level greater than or equal to 126 mg/dl (≥ 126 mg/dl) (ADA, 2014). If a
level greater than 126 mg/dl is indicated in the initial test, a second test is performed to confirm
the diabetes diagnosis (NIDDK, 2014). The FPG test has been the most common test used for
the diagnosis of diabetes because it is more convenient and less expensive than the OGTT
(NIDDK, 2014).
Oral Glucose Tolerance Test (OGTT)
The oral glucose tolerance test (OGTT) measures serial blood glucose levels after an
individual fasts for at least eight hours and again two hours after consuming a drink containing
75 g glucose dissolved in water (NIDDK, 2014). This protocol describes how the body
processes glucose (ADA, 2014). A two-hour OGTT reading of less than 140 mg/dl is defined
as normal (< 140 mg/dl); a reading of 140 mg/dl to 199 mg/dl indicates a diagnosis of
prediabetes (140 mg/dl < 199 mg/dl); and a reading greater than 200 mg/dl indicates a diagnosis
of diabetes (≥200 mg/dl) (ADA, 2014). The OGTT can be used to diagnose all categories of
diabetes. Research has shown that the OGTT is more sensitive indicator of the risk of
developing T2DM in comparison to the A1C and FPG, but it is less convenient to administer
due to its strict preliminary requirements (NIDDK, 2014).
T1DM Diagnosis and Treatment
All three diagnostic tests (A1C, FPG, and OGTT) can be utilized to diagnose T1DM in
all age groups (NIDDK, 2014). However, T1DM is most commonly diagnosed by a random
plasma glucose with a test value of greater than 200 mg/dl (ADA, 2016a). A random blood
glucose test can be administered at any time to check the blood glucose levels within a patient’s
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body. Regardless of the time since an individuals’ last meal, a random blood sugar level greater
than 200 mg/dl suggests diabetes (Mayo Clinic, 2014).
The A1C test is often used to screen for T1DM due to the lack of fasting needed to
administer the test. However, it is not recommended for the diagnosis of T1DM (NIDDK,
2014). The epidemiological studies that formed the basis for recommendations for the A1C test
to diagnosis diabetes only included adults; it is therefore unclear if A1C and its respective
diagnostic cut points should be utilized for diagnosing T1DM in children and adolescents (ADA
2017). Nevertheless, the A1C test is often still utilized for the testing of T1DM. If this test is
unavailable or not chosen, an FPG or random blood glucose test can be administered as well test
(Mayo Clinic, 2014).
A patient with hyperglycemia and symptoms characteristic of diabetes must be accurately
categorized as having T1DM or T2DM in order to be prescribed appropriate treatment. In order
to categorize the type of diabetes mellitus a blood test is administered; if autoantibodies and/or
ketones are present T1DM is suggested (Mayo Clinic, 2014).
In some cases the onset of T1DM presents with an episode of DKA followed by a
symptom free “honeymoon period,” where symptoms subside for weeks, months, and in some
cases a few years (Khardori, 2016, Approach Considerations, second paragraph). This remission
is caused by a partial return of endogenous insulin secretion; although the symptoms subside for
a period of time, ultimately the disease returns (Khardori, 2016).
As there is no cure for T1DM, individuals with this diagnosis rely on lifelong insulin
therapy (Khardori, 2016). After the diagnosis, patients should maintain regular medical
supervision in order to reduce A1C levels in accordance with their set diabetes treatment plan
(Mayo Clinic, 2014). Individuals with T1DM monitor glucose levels by pricking their finger to
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test several times (3 to 6) a day (JDRF, n.d.). People with this disease must carefully balance
insulin through needle injections several times a day or continuous infusion through a pump with
eating and physical activity (JDRF, n.d.).
In addition to T1DM, there exists another form of DM known as latent autoimmune
diabetes adults (LADA) and often referred to as type 1.5 diabetes mellitus (Basile et al., 2014).
LADA is a slower progressing form of T1DM because of the similar autoimmune destruction of
pancreatic beta cells and is often indistinguishable from T2DM due to its adult onset (Basile et
al., 2014). T2DM occurs when the body is not able to use insulin properly, a condition called
insulin resistance (WebMD, 2017).
T2DM Diagnosis and Treatment
Similar to T1DM, all of the diagnostic tests (A1C, FPG, and OGTT) can be administered
to diagnose T2DM. The A1C test is often used to diagnose diabetes. However, if an individual
is pregnant and/or has irregular hemoglobin (known as hemoglobin variants), which may alter
the results of the test. The FPG or OGTT are strong alternatives to test for T2DM in such cases
(Mayo Clinic, 2014).
Although T2DM can present with some similar symptoms as T1DM including increased
thirst, increased urination, blurry vision, numbness in extremities (ADA, 2015), it does not
exhibit an autoimmune destruction of beta cells within the pancreas or sudden onset of DKA
(ADA, 2016a). Obesity is a major indicator of the susceptibility to T2DM in the United States
(The Obesity Society, 2016) and is the hallmark of T2DM in North American children (Hannon
& Arslanian, 2015). The escalating rates of obesity the general population means that
individuals with T1DM are also more likely to be overweight/obese, making the clinical
distinction between T2DM and obese T1DM difficult (Hannon & Arslanin, 2015).
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In people who do not undergo periodic medical checkups, T2DM may go undiagnosed
for long periods of time because hyperglycemia develops gradually and symptoms may be
difficult to detect (ADA, 2016a). There are several risk factors associated with T2DM including
age, race, pregnancy, stress, genetics, and family history (The Obesity Society, 2016). Most
individuals with T2DM are overweight or obese (ADA, 2017). According to the 2016 Standards
of Medical Care in Diabetes, testing for prediabetes and/or diabetes should be considered in
adults of any age with a BMI (body mass index) greater than 25 who also exhibit one or more
additional risk factors (ADA, 2016a). Testing for prediabetes and/or diabetes is recommended
for children that are considered overweight (BMI > 85th percentile for age) that exhibit two
additional risk factors including family history, belonging to a racial/ethnic minority, maternal
history of diabetes, and/or onset of puberty (ADA, 2016a).
Approximately 90% of people living with T2DM are overweight or obese; the single best
predictor for T2DM is overweight or obesity defined by body mass index (The Obesity Society,
2016). The BMI is a ratio of weight to height (kg/m2) utilized to measure the degree of an
individual’s overweight or obesity (CDC, 2015c). According to the CDC, BMI ranges for adults
are defined as normal (BMI range 18.5< 25), overweight (BMI range 25.0 < 30) and obese (BMI
≥ 30) (CDC, 2016c). The risk of developing T2DM increases with age, obesity, and lack of
physical activity (ADA, 2016a). Figure 3 shows the correlation of prevalence rates of obesity
and T2DM diagnosed in US adults (Romero, 2016).
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Figure 3. Prevalence rates of obesity and diagnosed diabetes among US Adults. Copied from
Romero, 2016, p. 14.
Management of T2DM includes healthy heating, regular exercise, and regular blood
glucose monitoring, with or without oral medication or insulin therapy (Mayo Clinic, 2016).
One of the most commonly prescribed medications for T2DM is metformin, which helps the
body use insulin more effectively, basically reversing insulin resistance by facilitating transport
of glucose into cells (Mayo Clinic, 2016). Other common treatments are sulfonylureas and
meglitinides, classes of medications that stimulate the pancreas to secrete more insulin (Mayo
Clinic, 2016).
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Prediabetes Diagnosis and Treatment
Prediabetes is defined as a condition in which individuals display higher blood glucose
levels than normal, but not high enough to be classified as diabetes (ADA, 2016a). Individuals
with certain risk factors have a greater likelihood to develop prediabetes and/or T2DM. These
risk factors include age (especially > 45 years), being overweight (BMI range 25 <30) or obese
(BMI >30), family history of diabetes, certain racial/ethnic ancestry, and physical inactivity
(active < 3 times a week) (CDC, 2016c). Being overweight and/or obese plays a large role in the
progression of an individual from normal glucose tolerance (NGT) to the impaired fasting
glucose (IFG) and subsequent hyperglycemia that characterizes prediabetes (D’Adamo &
Caprio, 2011).
An individual with prediabetes has a greater risk for developing T2DM and other serious
health complication such as heart disease and stroke: early detection and prevention efforts
combat these adverse health effects (CDC, 2016c). Blood tests including A1C, FPG, and OGTT
are valuable tools to diagnose prediabetes because symptoms may not be noticeable to the
individual (NIDDK, 2014). Early detection of prediabetes is key to long-term health because
lifestyle modifications and/or medications have been proven effective methods for reversing
prediabetes and restoring normal glucose tolerance (NGT) (Brar et al., 2014).
Diabetes Morbidity and Mortality
While diabetes is recognized as a major international public health risk, according to the
International Diabetes Federation (IDF), the highest prevalence (11.5%) is reported in North
America and the Carribean (Jaacks, Siegel, Gujral, & Narayan, 2016). Although preventable,
diabetes remains a growing public health epidemic in the United States. In 2012, 29.1 million
Americans had diabetes, which increased from the 2010 estimate of 25.8 million Americans with

PEDIATRIC TYPE 2 DIABETES EPIDEMIC

19

diabetes (ADA, 2016b). Of the 29.1 million Americans living with diabetes, only 1.25 million
(4.29%) American children and adults have T1DM (ADA, 2016b). Figure 4 illustrates the
increasing prevalence of diabetes among adults ages 18 and over in the United States over the
past several decades.

Figure 4. Adult diabetes prevalence in the United States 1980-2014. Source: CDC, 2014, p. 1.
According to the CDC, T2DM accounts for majority (90-95%) of all diabetic cases
(ADA, 2016b). The severity of this disease is due to its increased risk factors for comorbid
conditions including cardiovascular disease, stroke, blindness, kidney disease, and amputations
(NIDDK, 2014). Of these long-term health complications, T2DM is the leading cause of
blindness (diabetic retinopathy), end stage kidney disease (diabetic nephropathy), and nontraumatic lower extremity amputations (diabetic neuropathy) (The Obesity Society, 2016).
Along with increased risk for adverse health outcomes, individuals with T2DM have a greater
risk (50% higher) of death in comparison with individuals that do not have diabetes (CDC,
2016c); because of this, diabetes is recognized as the seventh leading cause for death among
adults within the United States (CDC, 2015a).
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Diabetes Catastrophe and the Need for Prevention
Due to the increased burden of T2DM and its associated complications on health
outcomes, increased efforts to prevent T2DM have begun to identify at-risk individuals prior to
diabetes diagnosis (Abraham & Fox, 2013). Research clearly shows that if individuals with
prediabetes lose a modest amount of weight (5-7%) and increase physical activity (≥150 minutes
each week), they can delay or prevent the onset of T2DM (CDC, 2016b). Without weight loss
and increase in physical activity, 15-30% of individuals with prediabetes will develop T2DM
within five years (CDC, 2016b). Epidemiological and clinical trials have shown that the onset of
T2DM can be also delayed and/or be prevented through pharmacological intervention (Kong,
Luk, & Chan, 2016).
Due to the largely preventable nature of T2DM (The Obesity Society, 2016), multiple
organizations have provided screening recommendations for T2DM for adults. These include
The United States Preventive Services Task Force (USPSTF,
https://www.uspreventiveservicestaskforce.org/) and the American Diabetes Association (ADA,
http://www.diabetes.org/) (Pippitt, Li, & Gurgle, 2016). The USPSTF recommends screening
adult individuals aged 40 to 70 years that present as overweight or obese based on BMIs (Pippitt
et al., 2016). In contrast, the ADA recommends broader screening, including adults 45 years of
age or older regardless of risk, and they also include screening for prediabetes in their guidelines
(Pippitt et al., 2016). In order to address the magnitude of this disease, the CDC has
implemented an evidenced-based program, The National Diabetes Prevention Program to
prevent or delay the development of T2DM among adults with prediabetes (CDC, 2016b).
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The National Diabetes Prevention Program (DPP)
The Diabetes Prevention Program was a multifaceted clinical research study established
compare behavioral and pharmaceutical interventions including modest weight loss (5-7% body
weight) through dietary changes and increased physical activity or pharmacological treatment
with oral diabetes drug metformin in the prevention and/or delay of onset of T2DM in
participants (NIDDK, 2008). At baseline, study participants (n = 3,234) were all categorized as
overweight and had prediabetes, which are known risk factors for the development of T2DM
(NIDDK, 2008). In addition, many participants (45%) were from minority groups (African
American, Alaska Native, American Indian, Hispanic/Latino or Pacific Islander) all of whom are
at increased risk for developing T2DM (NIDDK, 2008). The participants were divided into four
groups: lifestyle intervention, metformin, placebo, and troglitizone group; the troglitizone group
was later discontinued when the drug was removed from the market due to adverse side effects
including liver damage (NIDDK, 2008). The DPP’s results indicated that participating
individuals at-risk for developing T2DM reduced their risk by 58% with only increased physical
activity and dietary modifications, making pharmaceutical intervention optional (NIDDK, 2008).
Along with the lifestyle intervention, the DPP also reported that metformin alone can also be
effective in helping delay the onset of diabetes (NIDDK, 2008).
In order to combat the rising epidemic of prediabetes and T2DM, the CDC introduced the
evidenced-based lifestyle intervention The National Diabetes Prevention Program (NDPP,
https://www.cdc.gov/diabetes/prevention/index.html). The NDPP is a year-long lifestyle
intervention program providing educational sessions, homework and feedback from a lifestyle
coach to optimize behavioral modifications and achieve 5-7% weight loss from baseline (CDC,
2016b).
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The program can be disseminated at any CDC-approved location that has taken the
proper steps to maintain fidelity and accuracy of disseminating the program according to CDC
DPP curriculum CDC (CDC, 2016b). The program is 12-month-long program with the initial six
months covering 16 lifestyle intervention topics and the last six months covering at least 10
additional modules (CDC, 2016b). The curriculum is delivered by DPP trained lifestyle coaches.
Although academic or medical credentials are not required, some lifestyle coaches may have the
following credentials: registered nurse (RN), registered dietician (RD), or certified diabetes
educator (CDE) (CDC, 2016b). Program attendance, physical activity minutes, food journals,
and BMI are measured to determine if program goals (moderate weight loss and increased
physical activity) are met to deter the onset of T2DM (CDC, 2016b).
Due to increased research and awareness of prediabetes as well as the evidenced-based
nature of the NDPP, the CDC has made the curriculum materials readily available for
community organizations (https://www.cdc.gov/diabetes/prevention/lifestyleprogram/curriculum.html) to adopt the evidenced-based approach to combat prediabetes and
T2DM at a local level.
Prediabetes is now a treatable condition and has an ICD-10 code (R73.09) for clinical
medical diagnosis and reimbursement purposes (CDC, 2016a). The adoption of a code for both
diagnosis and reimbursement has increased the ability for local organizations to disseminate and
deliver DPP program to combat prediabetes and assist in delaying the onset of T2DM.
The Medicare Diabetes Prevention Program (MDPP) is an expanded model that utilizes
structured behavioral change intervention to prevent T2DM among Medicare beneficiaries
diagnosed with prediabetes (Centers for Medicare & Medicaid Services [CMS], 2016). The
MDPP was approved for Medicare reimbursement in 2016 and will be reimbursable on or after
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January 1, 2018. In 2016, Medicare spent an estimated amount of $1,500 more on Part D
prescription drugs, $3,100 more for hospital and facility services, and $2,700 more in physician
and other clinical services for those with diabetes in comparison with those without diabetes
(CMS, 2016). The expansion of coverage for the MDPP will assist in the ability to prevent
T2DM in American and assist in the public health crisis of T2DM which is so costly among the
American health care system.
Pediatric T2DM Epidemic Overview
The rise of T2DM in the pediatric population and its long-term health risks are important
to address due to their effect on the overall health and life expectancy of today’s children and
adolescents. While traditionally T2DM is diagnosed after the age of forty, recently it is being
diagnosed in all age ranges, including during childhood and adolescence (The Obesity Society,
2016). The incidence of T2DM in children and adolescents has increased, with a current
estimated incidence of 5,000 new cases per year (Nadeau et al., 2016). Recent studies in
childhood and adolescents populations have identified that children and adolescents with T2DM
have an elevated risk for diabetes-related complications earlier in the course of the disease
(Hannon, 2014). In the adult population, the transitional prediabetic state of IGT is associated
with a high incidence (~10%) of vascular complications (D’Adamo & Caprio, 2011). However,
there has been major progress with lifestyle and/or pharmacological interventions that may
reverse and/or delay the onset of T2DM in adults (D’Adamo & Caprio, 2011). Thus it is
important to understand the development of T2DM in youth and its complications in the
pediatric population to identify best practices to achieve the same success.
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Youth Onset Prediabetes and T2DM and Categorization
Similar to the adult population, the onset of T2DM is a gradual progression mainly
affected by pancreatic decline in beta cell function (D’Adamo & Caprio, 2011) and/or insulin
resistance (Hannon & Arslanian, 2015). Insulin resistance places an increased demand for
pancreatic beta-cells to hypersecrete insulin, thereby increasing the risk for progressive beta-cell
failure characteristic of T2DM (D’Adamo & Caprio, 2011). The transition from NGT to T2DM
is preceded by an intermediate state of prediabetes, which is a risk factor for developing T2DM
(Hannon & Arslanian, 2015). Children and adolescents that have prediabetes are classified as
having IFG (FPG levels 100 – 125 mg/dL) or IGT (glucose values from OGTT of 140 –199
mg/dL) (Hannon & Arslanian, 2015). It has been proposed that hyperglycemia may worsen
insulin resistance and decreased beta-cell function, therefore increasing the risk of transitioning
from IGT to T2DM (Reinehr, 2013). While the transition from prediabetes to T2DM in adults is
usually a gradual process (5 to 10 years), meanwhile in youth there has been an increased
premature onset of T2DM observed which contributes to the notion of an accelerated process in
the pediatric demographic, exhibited by a shorter transition time between IGT and the
development of T2DM (D’Adamo & Caprio, 2011). The shorter duration of the prediabetes
phase in youth increases the need to better understand the causes of T2DM in the pediatric
demographic and the need to develop successful preventions.
Much like the adult population’s risk factors for T2DM, obesity is a major risk factor for
T2DM in United States youth (Hannon & Arslanian, 2015). This is alarming due to obesity
being identified as one of most important causes of the development of insulin resistance
(D’Adamo & Caprio, 2011). Common descriptors of a child diagnosed with T2DM are having a
genetic family history, being overweight and/or obese, entering puberty, being from an
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ethnical/racial minority group, and being biologically characterized as a female (Hannon &
Arslanian, 2015). These descriptors are important risk factors to address to limit the gaps in
research in understanding the youth onset of T2DM and to identify evidenced-based methods to
prevent the development of T2DM in youth. The ADA recommends screening at-risk children
for prediabetes and/or T2DM using the FPG or OGTT test every two years beginning at the age
of ten and/or the onset of puberty (Brar et al., 2014).
The same screening tests used for diagnostic purposes in the adult population can be
utilized to diagnose prediabetes and/or T2DM in youth. Although the FPG test is the preferred
method, the OGTT test is more sensitive due to its ability to detect individuals with IGT ( > 140
mg/dl), which is a major predictor of T2DM in youth (Brar et al., 2014). The requirement to fast
for both the FPG and the OGTT can make it difficult for pediatricians to obtain accurate results
given high rates of patience non-compliance; thus the A1C test has been considered an
alternative method to test (Brar et al., 2014). A substantial amount of diagnostic criteria for
T2DM is based on long-term health outcomes and validations for specific criteria that f is not
available or pediatric populations (ADA, 2016a). Although the A1C test is recommended for
adults, many pediatric health screeners use the adult cutoffs for FPG, A1C and OGTT tests due
to the lack of research on pediatric population diagnostic criteria (Brar et al., 2014).
Modifiable Risk Factors
A major modifiable risk factor for T2DM among youth is obesity (Hannon & Arslanian,
2015). According to the World Health Organization (2016), childhood obesity is one of the
largest public health challenges to face in the 21st century. The BMI is calculated by a person’s
weight (kg) divided by their height squared (m2). In the pediatric population (2 to 20 years),
BMI interpretation is age- and sex-specific and expressed as a percentile placement within the
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patient’s cohort (CDC, 2015c). In the pediatric population, a child with a BMI classified as
overweight falls within the 85th and 95th percentile (85th < 95th percentile) and with a BMI greater
than or equal to 95th percentile (> 95th percentile) are considered obese (CDC, 2016c).
Approximately 17% of American children are obese (CDC, 2014). Children that are overweight
and/or obese are more likely to continue to be overweight and/or obese in adulthood, develop
long term health issues such as diabetes, hypertension and cardiovascular diseases at a younger
age, and have a greater risk of premature death (WHO, 2016). An estimated 25% of children and
21% of adolescents that are obese (BMI > 95th percentile) were found to have IGT (D’Adamo &
Caprio, 2011).
The pediatric population exhibits similar patterns of transition from NGT to IGT that has
been identified in the adult population due to overweight and/or obesity (ADA, 2013).
Therefore, the already increasing public health risk of childhood obesity is contributing to
another rising epidemic of increased presence of T2DM in children.
Lifestyle habits including excess nutritional intake and decreased physical activity
(Hannon & Arslanian, 2015) are also modifiable risk factors that contribute to obesity, thus
contributing to T2DM. According to a statement issued by the United States Surgeon General
about childhood obesity, improper nutrition and inadequate physical activity are contributing
factors for the United States childhood overweight and obesity epidemic (The Office of Disease
Prevention and Health Promotion [ODPHP], 2017a). The rise in obesity, metabolic syndrome,
and diabetes has increased with the increase in daily caloric intake, especially among those
eating a western diet that is high in total fat and saturated fatty acids (Cree-Green, Triolo, &
Nadeau, 2013). The majority of Americans also exceed recommended amounts for sugar,
saturated fats, and sodium consumption (ODPHP, 2017b). According to the Dietary Guidelines
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for Americans 2015-2020, about 1/3 of the population have eating patterns low in vegetable and
fruit consumption as well as necessary dairy and oils (ODPHP, 2017b). Risks for metabolic
syndrome have shown a decrease in diets high in fruits, vegetables and whole grains (Cree-Green
et al., 2013). The Dietary Intervention Study in Children (DISC) evaluated the effects of a low
fat, high fiber diet during adolescence and showed benefits in both glycemic control and blood
pressure (Cree-Green et al., 2013).
Regular physical activity in children and adolescents contributes to a healthier lifestyle
and lowers the risk for development of chronic disease (ODPHP, 2017a). However, in the
United States there has been a recent decrease in overall physical activity level, especially in
girls, during their transition from childhood to adolescence which is an important time in which
overweight youth are at risk for developing T2DM (Cree-Gree et al., 2013). According to the
Physical Activity Guidelines for Americans (PAG), children and adolescents ages six to17 years
are recommended to perform one hour or more of physical activity per day, including aerobic-,
muscle-, and/or bone-strengthening activity (ODPHP, 2017a). Sedentary lifestyle has been
identified as a critical factor for the development of T2DM in youth (Cree-Green et al., 2013).
There have been several studies conducted to identify best practices in childhood obesity
prevention; such studies have addressed intervention targets of diet, physical activity, and
environmental components and its efficacy. The National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) launched an evidenced-based program called Ways to Enhance
Children’s Activity and Nutrition (WE CAN) to combat childhood obesity by encouraging
healthier nutrition, increased physical activity, and reduced sedentary activity (Zoorob et al.,
2013). This intervention takes a community level approach, informing community officials,
parents, and caretakers, and youth ages eight to thirteen (Zoorob et al., 2013). This community
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level approach is essential because a child’s environment and adult figures play an integral role
in the food choices made available for children. Lifestyle changes including increased physical
activity, decreased consumption of sugars, and improved overall diet are useful in combatting
unhealthy weight gain. Adult healthy lifestyle choices and behaviors are traditionally developed
in adolescence (Kelly, Melnyk, Jacobson, & O’Haver, 2011). Parents can play a large role for
younger children and their diet and physical activity behaviors by increasing healthy food access
and limiting use of technology (Evans et al., 2016). Adolescents rely less on parental figures to
provide avenues for healthy living and begin to make more independent choices about physical
activity and nutrition (Kelly et al., 2011). Several studies identified peer relationships and school
environment as important factors that influence healthy lifestyle choices and behaviors in
adolescence (Kelly et al., 2011). School based interventions have been useful in preventing
childhood obesity (Evans et al., 2016). The educational environment has the ability to provide
nutritional education, physical activity, healthier food access, and also may influence parental
involvement by educating parents during parental events (Evans et al., 2016).
Non-Modifiable Risk Factors
Non-modifiable risk factors for T2DM in youth include a strong family history, a mother
with gestational diabetes, minority groups and puberty (Hannon & Arslanian, 2015). It has been
reported that adults with one parent (first-degree relationship) with T2DM have a an increased
risk (30-40%) lifetime risk of developing T2DM, and individuals with two parents with T2DM
have an even greater risk (70%) for developing T2DM (Hannon & Arslanian, 2015). Evidence
from both animal and human studies also suggests an association of maternal obesity and
gestational diabetes mellitus with an increase in offspring’s obesity and T2DM in youth (Hannon
& Arslanian, 2015).
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Belonging to a racial/ethnic minority group has been long identified as a risk factor for
many chronic diseases. In the United States, American Indians (this term is used by the United
States Census) have the highest rates of youth-onset T2DM (Nadeau et al., 2016). While T2DM
occurs in all racial/ethnic groups, in the SEARCH study the incidence of T2DM among children
and adolescents varied by ethnicity, with some of the highest rates observed among youth (which
they defined as 15 to19 years) in minority populations (African Americans, Hispanics, and
Native Americans) (D’Adama & Caprio, 2011).
Puberty has also been identified as a major role in the development of T2DM in children
due to the increased resistance to the action of insulin (insulin sensitivity) (Reinehr, 2013).
During puberty, significant physiological changes occur, including up to an approximately 50%
reduction in insulin sensitivity in lean, healthy children (Nadeau et al., 2016). Puberty is
therefore a vulnerable time period for the development of dysglycemia due to this pubertyrelated transient insulin resistance (Hannon & Arslanian, 2015). Insulin sensitivity decreases
during puberty due to hormonal secretion including human growth hormone, testosterone, and
estrogen secretion, along with increased fat mass in females (Cree-Green et al., 2013). Studies
have shown that insulin resistance occurs prior to puberty, explained by the accumulation of fat
and rising insulin-like growth factor (Cree-Green et al., 2013). Insulin resistance peaks during
the time period of mid-puberty in normal weight youth; therefore being obese during puberty
may enhance the risk for developing T2DM in youth (Cree-Green et al., 2013).
Morbidity & Mortality
The incidence of T2DM in youth has increased drastically over the past 20 years (Nadeau
et al., 2016). According to the 2014 National Diabetes Statistics Report, in 2008 to 2009 the
incidence of youth (<20 years) was approximately 5,089 new cases (CDC, 2015b). Of the new
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cases of T2DM reported in the United States the greatest new cases were among children aged
10 to 19 years (ADA, 2016b). Figure 5 shows the incidence in both T1DM and T2DM among
American youth (< 20 years) categorized by race/ethnicity in the years 2008 and 2009.

Figure 5. Incidence in 2008 and 2009 for T1DM and T2DM in Americans < 20 years of age.
Copied from the 2014 National Diabetes Statistics Report (CDC, 2015b, p. 4).
Figure 5 shows that the 2014 National Diabetes Statistics Report found the highest
incidence of T2DM in adolescents (10 to 19 years of age) was identified in the Asian population,
followed by the African-American population (CDC, 2015b). Projections of the burden of
T2DM in the United States youth population (< 20 years) from the years 2010 to 2050 forecast
an increase from 20,203 to 30,111 cases, assuming a constant incidence over time (Hannon &
Arslanian, 2015). It is projected that one third of all children today will develop T2DM in their
lifetime (Canterbury & Hedlund, 2013). In the most recent epidemiologic analyses, the
prevalence T2DM in the pediatric population triples from the age group of 10 to 14 years to the
15 to 18 year age group and affects adolescent females with rates 60% higher than adolescent
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males (ADA, 2016b). Similar to the adult population, the transition from normal glucose
tolerance to T2DM in youth is preceded by an intermediate stage of prediabetes which is defined
by IFG (FPG values of 100-125 mg/dL) or IGT (OGTT values 140-199 mg/dL) (Hannon &
Arslanian, 2015). Among United States adolescents (12 to 19 years) prevalence rates of IFG,
IGT, and prediabetes were 13.1%, 3.4%, and 16.1%, respectively (Hannon & Arslanian, 2015).
The prevalence for prediabetes in overweight adolescents had a (2.6) higher rate of prediabetes
than adolescents categorized with a normal BMI (Hannon & Arslanian, 2015).
Current Treatment and Complications for T2DM in Youth
There is an unmet need for evidenced-based pediatric prevention programs specifically
targeting diabetes rather than obesity. Prior to the DPP study, the threshold of weight loss
necessary for diabetes prevention in adults (5-7%) was not established and the relative impact of
pharmaceutical versus behavioral intervention was unknown. Despite the many evidence-based
pediatric obesity interventions available (Ely et al., 2017), long-term chronic disease prevention
may not be achieved if biological thresholds are not met. The increasing incidence of T2DM in
adolescents is a serious public health problem that is complicated by the limited by the choices of
effective treatment options (Folsom & Hannon, 2017). Further, studies conducted on the natural
history of T2DM in youth show the disease is more aggressive in young people in comparison
with the adult populations (Hannon, 2014). Concurrent with the complications of earlier
development of T2DM among youth is the pediatric obesity epidemic, which also carries the
increased risk of the development of T2DM (Candela, Gutierrez, Dufek, Putney, & Mercer,
2012). Nearly 30-50% of American children diagnosed with T2DM, and nearly all of these are
categorized as overweight or obese (Candela et al., 2012). The increased risk for microvascular
and macrovascular complications developing earlier in life due to an early onset of T2DM in
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youth is an important part of the impetus to increase treatment of prediabetes and T2DM in the
youth population (Hannon & Arslanian, 2015).
Barriers to Comprehensive Treatment
There is an unmet need for evidenced-based pediatric prevention programs targeting
diabetes rather than obesity. Prior to the TODAY study results, there were few data to guide
treatment for prediabetes and/or T2DM in the pediatric population; most recommendations were
based on studies in adults with T2DM (Hannon & Arslanian, 2015). The preliminary treatments
for adults with prediabetes and/or T2DM are pharmacological treatments including metformin
(NIDDK, 2008) and lifestyle interventions, including improved nutrition habits and increased
physical activity; these interventions have not been studied extensively among the youth
population (Folsom & Hannon, 2017). Currently, the only pharmacological treatments approved
for children with T2DM are metformin and insulin (Folsom & Hannon, 2017).
Another complicating factor to implementing lifestyle interventions in children are: their
limited participation in the type or quality of food purchased, how the meal is prepared, and/or
the location of their home and access to safe places to exercise (Folsom & Hannon, 2017). The
treatment of T2DM in youth requires a multifaceted approach through a diabetes team including
the patient, family, physician/clinical team, behavioral specialists, dieticians, and school
personnel (Hannon & Arslanian, 2015).
Many pediatric lifestyle interventions have focused on youth affected by obesity rather
than prediabetes and T2DM (Nadeau et al., 2016). The majority of these interventions focus on
individual behavior modification, utilizing health education to target nutrition and physical
activity and social cognitive models (Nadeau et al., 2016). Obesity is a major risk factor in the
development of prediabetes and T2DM, thus increasing the focus of prevention of prediabetes
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and T2DM in pediatric interventions has significant benefits to improve the quality of life of
children (Hannon & Arslanian, 2015).
The TODAY study, a multifaceted study (funded by the NIDDK), researched treatment
strategies and options for adolescents and youth with T2DM (Linder, Fradkin, & Rodgers, 2013).
The results of the TODAY study showed that: primarily, metformin monotherapy provided
glycemic control in only half the participants; secondly, that the combination of metformin and
rosiglitazone improved the durability of glycemic control; and lastly, that metformin combined
with lifestyle intervention was no better than metformin alone in maintain glycemic control
(Linder et al., 2013). Further analysis of the data on insulin resistance and secretion derived
from serial OGTT in the TODAY study, suggest that early and rapid deterioration of beta-cell
function in these youth in comparison with adults newly diagnosed T2DM (Linder et al., 2013).
The HEALTHY study (funded by the NIDDK with support from the ADA) demonstrated that
population-based programs could lower rates of obesity and hyperinsulinemia in middle schoolaged children (Linder et al., 2013). The challenges of effectively treating T2DM in children
compound the need for further research into effective prevention of obesity and diabetes (Linder
et al., 2013).
The Need for Effective Youth T2DM Prevention
The rising prevalence of overweight children as well as children with type 2 diabetes has
prompted the adaptation and development of pediatric diabetes prevention programs that parallel
those for adults (Candela et al., 2012). However, these programs are only emergent and are few
in number. The following section summarizes and critiques the pediatric DPPs found during the
research for this project and their use of theories and research to adapt existing DPPs for youth.
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Existing Youth Diabetes Prevention Programs (YDPPs)
There has been increasing research and programs implemented to prevent and treat the
early onset of T2DM. A comprehensive review of the literature, about emerging diabetes
prevention program was conducted through research databases and youth children hospitals.
Three diabetes prevention programs and/or clinics for youth were identified. Their basic
characteristics are listed in Table 1 and a summary of strengths and weaknesses for each program
follows.
Table 1
Characteristics of Emerging Youth Diabetes Prevention Programs
Adapted Diabetes
Prevention
Program
University of
Nevada, Las Vegas

Programs
Affiliation

Get a Move On
Indiana
University

PowerHouse
Indiana University

Target Audience

>10 years

>10 years

6th, 7th, 8th, &
9th graders

7-16 years

Intervention
Setting

CommunitySetting

CommunitySetting

School Classroom

CommunitySetting

Curriculum

Social Cognitive
Theory

Social Cognitive
Theory

Sociocultural
Theory

Smart Moves™

Length/Delivery

Once a Week for
12 weeks

Twice a Week for
16 weeks

Five times a week
for 10 weeks

Twice a week
for six months

Bright Bodies
Yale University

Indiana University: Riley Children’s Hospital Diabetes Prevention Clinic
Indiana University School of Medicines’ Youth Diabetes Prevention Clinic is operated
within Riley’s Children Hospital (Riley Children’s Health, Indiana University Health, 2017).
This clinic is designed to diagnose children and adolescents (> 10 years of age) that present with
prediabetes and/or have elevated risk factors for the development of T2DM (Riley Children’s
Health, Indiana University Health, 2017). The clinical treatment program utilizes the DPP
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modified for use with patients and their families (Riley Children’s Health, Indiana University
Health, 2017). Identified risk factors are family history of T2DM, elevated blood sugar levels,
and obesity and many of the adolescents are referred to the program by their primary care doctor
(Riley Children’s Health, Indiana University Health , 2017). Each patient receives and
individualized coaching plan to increase physical activity, consultation with dietician to improve
overall diet (Riley Children’s Health, Indiana University Health, 2017).
The strengths of the Riley Children’s Hospital YDPP include the utilization of core
constructs of the NDPP (lifestyle interventions) by providing education about behavioral
modification not only to the patient, but to his/her family (Riley Children’s Health, Indiana
University Health, 2017). Along with modifying the DPP, YDPP clinic also uses goal-setting
strategies to implement therapeutic lifestyle changes in both the children and their families
(Riley Children’s Health, Indiana University Health, 2017). The treatment model aims to
prevent T2DM in adolescents at the local, state, and national level with continuous
communication with providers (Riley Children’s Health, Indiana University Health, 2017). An
individualized plan for each patient allows for the accommodation of individualized needs for a
patients behavioral change (Riley Children’s Health, Indiana University Health, 2017).
The clinic has implemented several programs in order to identify the best methods to
prevent diabetes (personal communication, Julie Pike, RD, CDE). The first program, known as
Get a Move On, emphasized a curriculum of health education sessions centered on education
about fruits and vegetables, healthy breakfast, portion sizes, decreasing the amount of sugary
drinks and snacks, and eating at home (personal communication, Julie Pike, RD, CDE). Each
topic was covered over two weeks and incorporated the mother as gatekeeper to the children’s
food source (personal communication, Julie Pike, RD, CDE).
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Powerhouse, an improved program based on the initial program Get a Move On, is a 16week-long program that began in January 2017. It is aimed at incorporating separate lifestyle
interventions for children and their parents. The clinic is measuring the effects these separate,
targeted educational interventions have on preventing T2DM in youth (personal communication,
Julie Pike, RD, CDE). The purpose of this group intervention is to provide educational sessions
that are better tailored for the target learning styles, which differ throughout stages of
developments, as well as provide social support (personal communication, Julie Pike, RD, CDE).
University of Nevada, Las Vegas’s: Adapted DPP
The University of Nevada, Las Vegas conducted a feasibility case study that modified the
NDPP curriculum (CDC, 2016b) for adolescent populations (7th to 10th graders) in a school
setting. Modifying the DPP for adolescent use could benefit the fight against the pediatric
T2DM epidemic. School-based programs are considered a beneficial approach due to the great
amount of time students spend in school-based environments (Candela et al., 2012). Students
participated in 45-minute sessions, five days a week, conducted daily during a regular class
period for a total of ten weeks (Candela et al., 2012). The study demonstrated that instruction,
using the CDC’s DPP curriculum specifically tailored to adolescents, positively impacted their
dietary knowledge, but not weight Results from this study indicate that the DPP intervention
increased positive lifestyle behaviors including improved reported dietary habits and increased
reported physical activity. However, this association as only identified in the younger grade
levels (7th and 8th graders) (Candela et al., 2012). This was explained by the possible
commitment to learning diminishes as adolescents transition to high school and become more
focused on social groups and relationships (Candela et al., 2012). The study demonstrated that
instruction, using the CDC’s DPP curriculum specifically tailored to adolescents, positively
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impacted their dietary knowledge, but not weight (Candela et al., 2012). Further analysis of the
modified DPP program to identify the proper age group to target with this modification because
high school and middle school students have higher levels of disengagement than elementary
students as well as increased freedom to make choices about their diet (Candela et al., 2012).
Yale University’s: Bright Bodies Weight Management Program for Children
The Bright Bodies Weight Management Program for Children (Bright Bodies) is a weight
management program operated through the Yale University Pediatric Obesity Clinic tailored for
children ages seven to sixteen years of age (Yale Center for Clinical Investigation and Pediatric
Endocrinology, Yale School of Medicine, n.d.). It is a comprehensive program that utilizes the
Smart Moves program curriculum, which includes nutrition education, behavior modification and
exercise (Savoye, 2010). This program is a family-based, lifestyle intervention tailored for
inner-city youth and their families (Savoye et al., 2014).
The Bright Bodies program showed success in limiting weight gain and improving body
composition, insulin sensitivity, and lipids compared with the control group that received
conventional dietary counseling (Savoye et al., 2014).
Bright Bodies conducted another study with a goal to compare the effects of Bright
Bodies programs and standard clinical care on glucose tolerance in obese adolescents with
elevated OGTT levels (Savoye et al., 2014). Program participants (n=75) were recruited for the
study from Yale Pediatric Obesity Clinic to increase screening for IGT in obese children and
adolescents being treated by pediatric practices in New Haven, Connecticut (Savoye et al.,
2014). The program was administered twice a week for six months which included two 50minute exercise sessions per week, one weekly weigh-in and 40-minute nutrition/behavior
educational sessions (Savoye et al., 2014).
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The primary results of the study showed that Bright Bodies program significantly
decreased OGTT values in children at high risk for diabetes after six months in comparison with
children that received standard of care (Savoye et al., 2014). The findings indicate that the
Bright Bodies intervention improved glucose tolerance in obese youth with prediabetes (Savoye
et al., 2014). Notably, the curriculum for the Bright Bodies has served as a basis for several
pediatric obesity programs throughout the United States and the standardized curriculum has the
potential to cut training time, salary costs, and improve a more standardized dissemination of the
program (Savoye et al., 2014). Limitations of the Bright Bodies program include the major
commitment required from families, communities, and care providers (Savoye et al., 2014).
Discussion and Recommendations
The aim of this project was to identify the best-practices for implementing prevention
programs for prediabetes and T2DM due to the critical importance of diagnosing and treating
dysglycemia in youth due to the early complications of childhood obesity and T2DM (Nowicak
et al., 2011). Currently three programs are utilizing the best practices of the CDC’s DPP,
including adapted lifestyle interventions that have been proven successful in adults (NIDDK,
2008) and adopting a team approach that includes the patient, their family, physician, and
behavioral specialists (Hannon & Arslanian, 2015). The major concern for each of the programs
is to include the family and/care provider in the treatment program and to establish a community
presence of care, including follow up with pediatrician to regularly monitor a child’s progress in
maintaining safe glucose levels (personal communication, Julie Pike, RD, CDE). The
professional literature seems to place the burden of prevention on healthcare professionals, but it
must be a shared responsibility between the family, school, neighborhoods, the food industry,
and policy makers (Hannon & Arslanian, 2015).
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To facilitate the increased modification and implementation of lifestyle intervention
programs to address prediabetes and T2DM in youth, it is essential to conduct follow up studies
for the present evidenced-based programs being implemented today. Continued research is
needed to improve existing and establish new-evidence based DPP program curricula readily
available for dissemination of DPP programs in youth.
In addition to lack of studies outlining YDPP’s and there success, there is also a lack of
approved pharmacological agents to be used when metformin, the only approved therapy for
children, fails in youth (Hannon & Arslanian, 2015). Further identification of pharmacological
interventions for prediabetes and/or T2DM in youth is necessary in order to assist reverse
prediabetes and/or delay the onset of T2DM in youth in conjunction with YDPPs.
Recommendations developed from this project include modifying and disseminating
programs that can be administered at school locations and during school hours in order to limit
the obstacles in youth with T2DM like transportation, access to care to identify eligibility
criteria, and the reluctance to participate with parents/guardians (Folsom & Hannon, 2017).
Long-term physical and psychosocial consequences can stem from developing T2DM in early
developmental stages (Folsom & Hannon, 2017). Continued research is needed to improve and
establish evidence-based curricula readily available for dissemination of DPP programs for
youth. Increased research designed to minimize the gaps in literature about the pathophysiology
of T2DM in youth, the ability to reverse prediabetes and delay the onset of T2DM, and increase
the availability of and participation in these programs will improve the chances for successful
program implementation to combat the epidemic of T2DM in youth within the United States.
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Appendix A: List of Competencies Met in CE
Wright State Program Public Health Competencies Checklist
Assess and utilize quantitative and qualitative data.
Apply analytical reasoning and methods in data analysis to describe the health of a community.
Apply behavior theory and disease prevention models to develop community health promotion and
intervention programs.
Communicate public health information to lay and/or professional audiences with linguistic and
cultural sensitivity.
Make evidence-informed decisions in public health practice.
Evaluate and interpret evidence, including strengths, limitations, and practical implications.
Demonstrate ethical standards in research, data collection and management, data analysis, and
communication.

Concentration Specific Competencies Checklist

Health Promotion and Education:
Area 1: Assess Needs, Assets and Capacity for Health Education
1.3 Analyze factors that foster or hinder the learning process
1.4 Identify factors that foster or hinder skill building
1.5 Analyze factors that foster or hinder skill building
1.6 Synthesize assessment findings
Area 2: Plan Health Education Programs
2.1 Use assessment results to inform the planning process
2.2 Select planning model(s) for health education
2.3 Develop goal statements
2.7 Organize health education into a logical sequence
Area 3: Implement Health Education
3.5 Use evaluation findings to plan future training
Area 4: Conduct Evaluation and Research Related to Health Education
4.1 Create purpose statement
4.2 Develop evaluation/research questions
4.3 Assess the merits and limitations of qualitative and quantitative data collection for research
4.6 Develop data analysis plan for research
4.9 Disseminate research findings through professional conference presentations
Area 5: Manage Health Education Programs
5.7 Use communication strategies to obtain program support
5.10 Synthesize data for purposes of reporting
Area 6: Serve as a health education resource person
6.4 Identify existing resources that meet training needs
6.5 Use learning theory to develop or adapt training programs
6.8 Use a variety of resources and strategies
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